Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- SNOW +24.1%, CHPT +17.5%, NTSK +11.2%, WOOF +9.9%, AGX +7.7%, FIVE +6.4% (also authorizes $600 mln share repurchase program), AMBR +5.9%, PVH +3.7%, BRC +3.7%, ZGN +3.2%, GCO +3%, CIEN +1.8%
Other news:
- NYXH +13.9% (ACCESS U.S. study meets primary safety and efficacy endpoints)
- CLYM +13.9% (posts Phase 1 CLYM116 data supporting every-12-week dosing in IgA nephropathy)
- HCM +11.2% (HUTCHMED licenses HMPL-A830 to GSK in deal worth up to $1.295 bln)
- PHVS +4.4% (presents translational, nonclinical, and clinical data at Bradykinin Symposium 2026)
- GPRK +2.7% (to enter Venezuela through Bare Block deal; Grupo Gilinski to become controlling shareholder)
- DOV +2.6% (launches TraceIQ pharmaceutical traceability platform)
- IVA +2.5% (completes last patient visit in Phase 3 NATiV3 trial; topline MASH data expected Q4)
- MIR +2.4% (CFO insider purchase)
- CCCC +2.1% (to present Phase 1 cemsidomide biomarker data in relapsed/refractory multiple myeloma at IMS)
- HRZN +1.9% (provides $15 mln senior credit facility to Bioness Medical)
- NET +1.9% (adds support for Cursor Cloud Agents on Sandboxes)
- DEC +1.5% (to acquire Birch for $1.8 bln, expanding Permian Basin footprint)
- UBER +1.5% (Uber & Wayve Launch first-ever autonomous rides in the UK)
- GNW +1.4% (expands repurchase program by $500 mln)